176 related articles for article (PubMed ID: 11173124)
1. Therapeutic targets in radiotherapy.
Brown JM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):319-26. PubMed ID: 11173124
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
Shi Y; Wu J; Mick R; Cerniglia GJ; Cohen-Jonathan E; Rhim JS; Koch CJ; Bernhard EJ
Prostate; 2005 Jan; 62(1):69-82. PubMed ID: 15389805
[TBL] [Abstract][Full Text] [Related]
3. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
Cohen-Jonathan E; Evans SM; Koch CJ; Muschel RJ; McKenna WG; Wu J; Bernhard EJ
Cancer Res; 2001 Mar; 61(5):2289-93. PubMed ID: 11280800
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.
Cohen-Jonathan E; Muschel RJ; Gillies McKenna W; Evans SM; Cerniglia G; Mick R; Kusewitt D; Sebti SM; Hamilton AD; Oliff A; Kohl N; Gibbs JB; Bernhard EJ
Radiat Res; 2000 Aug; 154(2):125-32. PubMed ID: 10931682
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
7. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
Brown JM; Lemmon MJ
Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
[TBL] [Abstract][Full Text] [Related]
8. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
[TBL] [Abstract][Full Text] [Related]
9. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors as radiation sensitizers.
McKenna WG; Muschel RJ; Gupta AK; Hahn SM; Bernhard EJ
Semin Radiat Oncol; 2002 Jul; 12(3 Suppl 2):27-32. PubMed ID: 12174342
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase inhibitors as radiation sensitizers.
Brunner TB; Gupta AK; Shi Y; Hahn SM; Muschel RJ; McKenna WG; Bernhard EJ
Int J Radiat Biol; 2003 Jul; 79(7):569-76. PubMed ID: 14530152
[TBL] [Abstract][Full Text] [Related]
12. The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities.
Feldkamp MM; Lau N; Guha A
Ann N Y Acad Sci; 1999; 886():257-60. PubMed ID: 10667233
[No Abstract] [Full Text] [Related]
13. Signaling inhibition with radiation in colorectal cancer: clinical trials.
McKenna WG; Muschel RJ; Gupta A; Hahn S; Bernhard EJ
Semin Oncol; 2003 Jun; 30(3 Suppl 6):56-67. PubMed ID: 12802796
[TBL] [Abstract][Full Text] [Related]
14. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
15. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the ras oncogene as therapeutic targets.
Ghobrial IM; Adjei AA
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
[TBL] [Abstract][Full Text] [Related]
17. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
Cox AD
Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
[TBL] [Abstract][Full Text] [Related]
20. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death.
Ader I; Toulas C; Dalenc F; Delmas C; Bonnet J; Cohen-Jonathan E; Favre G
Oncogene; 2002 Sep; 21(39):5998-6006. PubMed ID: 12203112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
